Linked Life Data

10437863

Source:http://linkedlifedata.com/resource/pubmed/id/10437863

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9176
pubmed:dateCreated
1999-8-12
pubmed:abstractText
Stratum 2 of the Ramipril Efficacy in Nephropathy (REIN) study has already shown that in patients with chronic nephropathies and proteinuria of 3 g or more per 24 h, angiotensin-converting enzyme (ACE) inhibition reduced the rate of decline in glomerular filtration and halved the combined risk of doubling of serum creatinine or end-stage renal failure (ESRF) found in controls on placebo plus conventional antihypertensives. In REIN stratum 1, reported here, 24 h proteinuria was 1 g or more but less than 3 g per 24 h.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0140-6736
pubmed:author
pubmed:issnType
Print
pubmed:day
31
pubmed:volume
354
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
359-64
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
pubmed:affiliation
Mario Negri Institute for Pharmacological Research, Clinical Research Centre for Rare Diseases, Aldo e Cele Dacco Villa Camozzi, Ranica, Bergamo, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study